129 related articles for article (PubMed ID: 36629898)
1. Duplex-immunoassay of ovarian cancer biomarker CA125 and HE4 based carbon dot decorated dendritic mesoporous silica nanoparticles.
Wang ZX; Ding SN
Analyst; 2023 Jan; 148(3):683-689. PubMed ID: 36629898
[TBL] [Abstract][Full Text] [Related]
2. An amplified comparative fluorescence resonance energy transfer immunosensing of CA125 tumor marker and ovarian cancer cells using green and economic carbon dots for bio-applications in labeling, imaging and sensing.
Hamd-Ghadareh S; Salimi A; Fathi F; Bahrami S
Biosens Bioelectron; 2017 Oct; 96():308-316. PubMed ID: 28525848
[TBL] [Abstract][Full Text] [Related]
3. The Role of Dendritic Mesoporous Silica Nanoparticles' Size for Quantum Dots Enrichment and Lateral Flow Immunoassay Performance.
Gao F; Liu Y; Lei C; Liu C; Song H; Gu Z; Jiang P; Jing S; Wan J; Yu C
Small Methods; 2021 Apr; 5(4):e2000924. PubMed ID: 34927850
[TBL] [Abstract][Full Text] [Related]
4. Point-of-care testing: a disposable label-free electrochemical CA125 and HE4 immunosensors for early detection of ovarian cancer.
Bilgi Kamaç M; Altun M; Yılmaz M; Yılmaz Aktan A; Aktan S; Sezgintürk MK
Biomed Microdevices; 2023 May; 25(2):18. PubMed ID: 37140852
[TBL] [Abstract][Full Text] [Related]
5. A label-free dual immunosensor for the simultaneous electrochemical determination of CA125 and HE4 biomarkers for the early diagnosis of ovarian cancer.
Bilgi Kamaç M; Altun M; Yilmaz M; Sezgintürk MK
Anal Bioanal Chem; 2023 Apr; 415(9):1709-1718. PubMed ID: 36719438
[TBL] [Abstract][Full Text] [Related]
6. Emission Wavelength Switchable Carbon Dots Combined with Biomimetic Inorganic Nanozymes for a Two-Photon Fluorescence Immunoassay.
Zhan Y; Yang S; Luo F; Guo L; Zeng Y; Qiu B; Lin Z
ACS Appl Mater Interfaces; 2020 Jul; 12(27):30085-30094. PubMed ID: 32530596
[TBL] [Abstract][Full Text] [Related]
7. Fluorescence turn-on immunosensing of HE4 biomarker and ovarian cancer cells based on target-triggered metal-enhanced fluorescence of carbon dots.
Han C; Chen R; Wu X; Shi N; Duan T; Xu K; Huang T
Anal Chim Acta; 2021 Dec; 1187():339160. PubMed ID: 34753571
[TBL] [Abstract][Full Text] [Related]
8. The Establishment of an HE4-CLIA Method and the Combined Analysis of HE4 and CA125 in Ovarian Cancer.
Zhang Q; Wang CR; Yu JP; Ma Q; Xu WW
J Clin Lab Anal; 2016 Sep; 30(5):709-18. PubMed ID: 26990679
[TBL] [Abstract][Full Text] [Related]
9. In Situ Synthesis of Highly Fluorescent, Phosphorus-Doping Carbon-Dot-Functionalized, Dendritic Silica Nanoparticles Applied for Multi-Component Lateral Flow Immunoassay.
Hu JX; Ding SN
Sensors (Basel); 2023 Dec; 24(1):. PubMed ID: 38202881
[TBL] [Abstract][Full Text] [Related]
10. Rational Design of Dendritic Mesoporous Silica Nanoparticles' Surface Chemistry for Quantum Dot Enrichment and an Ultrasensitive Lateral Flow Immunoassay.
Gao F; Lei C; Liu Y; Song H; Kong Y; Wan J; Yu C
ACS Appl Mater Interfaces; 2021 May; 13(18):21507-21515. PubMed ID: 33939415
[TBL] [Abstract][Full Text] [Related]
11. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.
Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J
Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
[TBL] [Abstract][Full Text] [Related]
13. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
[TBL] [Abstract][Full Text] [Related]
14. Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer.
Park Y; Kim Y; Lee EY; Lee JH; Kim HS
Int J Cancer; 2012 Mar; 130(5):1136-44. PubMed ID: 21484794
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.
Suri A; Perumal V; Ammalli P; Suryan V; Bansal SK
Sci Rep; 2021 Aug; 11(1):17308. PubMed ID: 34453074
[TBL] [Abstract][Full Text] [Related]
16. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
17. Research on application value of combined detection of serum CA125, HE4 and TK1 in the diagnosis of ovarian cancer.
Xi QP; Pu DH; Lu WN
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4536-4541. PubMed ID: 29131263
[TBL] [Abstract][Full Text] [Related]
18. CA125 and HE4: Measurement Tools for Ovarian Cancer.
Zhao T; Hu W
Gynecol Obstet Invest; 2016; 81(5):430-5. PubMed ID: 27160726
[TBL] [Abstract][Full Text] [Related]
19. Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer.
Leung F; Bernardini MQ; Brown MD; Zheng Y; Molina R; Bast RC; Davis G; Serra S; Diamandis EP; Kulasingam V
Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1333-40. PubMed ID: 27448593
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review.
Dochez V; Caillon H; Vaucel E; Dimet J; Winer N; Ducarme G
J Ovarian Res; 2019 Mar; 12(1):28. PubMed ID: 30917847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
